Product image of Isoprotrace (Gozetotide) supplied by GNH India

Isoprotrace

Active Ingredient:
Gozetotide
Origin:
EU

Isoprotrace (Gozetotide)

Gozetotide, the active ingredient in Isoprotrace, is a drug of unknown class presented as an unknown strength in an unknown dosage form for intravenous use. It is currently under investigation and no specific therapeutic indication has been publicly disclosed.

GNH India supplies Isoprotrace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Billev Pharma Aps

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Isoprotrace (gozetotide) is listed without a publicly identified therapeutic class, and no specific clinical indications have been disclosed.

  • No disclosed indication: No specific therapeutic use has been publicly announced.
  • No disclosed indication: No approved indication is available in regulatory databases.
  • No disclosed indication: Clinical application remains undefined pending further data.

How It Works

  • The exact pharmacological mechanism of gozetotide has not been publicly disclosed. It is presumed to interact with molecular targets under clinical investigation, but detailed pathways and receptor engagements remain confidential.

Side Effects

Adverse reaction information for Isoprotrace has not been fully characterized.

Common Side Effects

  • No specific common adverse reactions have been reported.
  • No documented frequency of mild events is available.

Serious or Rare Side Effects

  • No specific serious adverse reactions have been reported.
  • No rare events have been identified in the public domain.

Precautions & Warnings

Given the limited public data, standard clinical vigilance is recommended when using Isoprotrace.

  • Clinical monitoring: Observe patients for any unexpected signs or symptoms.
  • Allergy assessment: Verify absence of known hypersensitivity to the product.
  • Concomitant therapy review: Evaluate other intravenous agents for compatibility.
  • Renal/hepatic function: Consider baseline organ function before administration.
  • Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Interaction data for Isoprotrace are not publicly available.

Major Interactions (Avoid)

  • No known major drug interactions have been identified.
  • Avoid co‑administration with agents that cause severe infusion reactions until further data emerge.

Moderate Interactions (Monitor Closely)

  • No documented moderate interactions are currently reported.
  • Monitor for potential additive effects with other biologics or immunomodulators.
  • Observe for changes in laboratory parameters when combined with nephrotoxic or hepatotoxic drugs.

Frequently Asked Questions

Isoprotrace contains the active ingredient gozetotide. At present, no specific therapeutic indication has been publicly disclosed, and the product is considered investigational pending further clinical data.

The precise mechanism of action of gozetotide has not been released publicly. It is believed to target molecular pathways under investigation, but detailed pharmacological effects remain confidential.

Dosing for Isoprotrace is determined by the prescribing clinician based on the individual patient’s condition and the specific clinical protocol. No standard dose is publicly available.

Safety information for gozetotide during pregnancy or lactation has not been established. The product should be used only if the potential benefit justifies any potential risk to the mother or infant.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Because the therapeutic class and approved indications for gozetotide are not publicly defined, direct comparisons with alternative agents cannot be made at this time.

Isoprotrace should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow all cold‑chain handling procedures during transport and use.

Isoprotrace is supplied for intravenous administration. The exact infusion rate and protocol are determined by the treating physician according to the clinical context.

Serious or rare adverse reactions have not been reported in the public domain. Clinicians should monitor patients closely for any unexpected infusion‑related events or hypersensitivity reactions.

Patients with known hypersensitivity to any component of the formulation should avoid Isoprotrace. Until more safety data are available, use in populations without clear benefit‑risk assessment is not recommended.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gozetotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT